{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-338008","form_type":"8-K","ticker":"ALEC","cik":"0001653087","company_name":"Alector, Inc.","filed_at":"2026-08-06T20:10:49+00:00","discovered_at":"2026-08-06T20:11:31.330108+00:00","generated_at":"2026-08-06T20:14:10.732127+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Alector Q2 net loss narrows to $23M; cash runway through 2027; AL137 IND targeted Q1 2027","bullets":["Net loss of $23.0M ($0.21/share) vs $30.5M ($0.30/share) in Q2 2025; revenue $3.3M (down from $7.9M).","Cash, equivalents, and investments $172.8M as of June 30, 2026; runway at least through 2027.","Lead ABC-enabled anti-Aβ antibody AL137 selected; IND submission targeted Q1 2027 with first-in-human dosing in Australia by April 2027.","Tau siRNA program AL064/AL164 advancing into IND-enabling studies; AL050 GCase ERT for PD in preclinical development.","R&D expenses fell to $19.5M from $27.6M; G&A expenses fell to $8.3M from $14.4M, driven by workforce reductions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-338008","json":"https://secwatch.observer/filing/0001193125-26-338008.json","markdown":"https://secwatch.observer/filing/0001193125-26-338008.md","text":"https://secwatch.observer/filing/0001193125-26-338008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1653087/000119312526338008/0001193125-26-338008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1653087/000119312526338008/alec-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:14:10.732127+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}